Horst Lindhofer

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

M. M. Heiss, P. Murawa, P. Koralewski et al. · International Journal of Cancer · 2010 · 551 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Alexander Burges, Pauline Wimberger, Carolin Kümper et al. · Clinical Cancer Research · 2007 · 257 citations

Medicine, Oncology, Pharmacology +17

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

Horst Lindhofer, Ralph Mocikat, Boris Steipe et al. · The Journal of Immunology · 1995 · 208 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

Reinhard Zeidler, G. Reisbach, Barbara Wollenberg et al. · The Journal of Immunology · 1999 · 200 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert et al. · Clinical Cancer Research · 2006 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17